A Comparison of Virological Suppression and Rebound between Indigenous and Non-Indigenous Persons Initiating Combination Antiretroviral Therapy in a Multisite Cohort of Individuals Living with HIV in Canada
Free accessResearch articleFirst published online May, 2017
A Comparison of Virological Suppression and Rebound between Indigenous and Non-Indigenous Persons Initiating Combination Antiretroviral Therapy in a Multisite Cohort of Individuals Living with HIV in Canada
This study compared time to virological suppression and rebound between Indigenous and non-Indigenous individuals living with HIV in Canada initiating combination antiretroviral therapy (cART).
Methods
Data were from the Canadian Observational Cohort collaboration; eight studies of treatment-naive persons with HIV initiating cART after 1/1/2000. Fine and Gray models were used to estimate the effect of ethnicity on time to virological suppression (two consecutive viral loads [VLs] <50 copies/ml at least 3 months apart) after adjusting for the competing risk of death and time until virological rebound (two consecutive VLs >200 copies/ml at least 3 months apart) following suppression.
Results
Among 7,080 participants were 497 Indigenous persons of whom 413 (83%) were from British Columbia. The cumulative incidence of suppression 1 year after cART initiation was 54% for Indigenous persons, 77% for Caucasian and 80% for African, Caribbean or Black (ACB) persons. The cumulative incidence of rebound 1 year after suppression was 13% for Indigenous persons, 6% for Caucasian and 7% for ACB persons. Indigenous persons were less likely to achieve suppression than Caucasian participants (aHR=0.58, 95% CI 0.50, 0.68), but not more likely to experience rebound (aHR=1.03, 95% CI 0.84, 1.27) after adjusting for age, gender, injection drug use, men having sex with men status, province of residence, baseline VL and CD4+ T-cell count, antiretroviral class and year of cART initiation.
Conclusions
Lower suppression rates among Indigenous persons suggest a need for targeted interventions to improve HIV health outcomes during the first year of treatment when suppression is usually achieved.
References
1.
CohenM.S., SmithM.K., MuessigK.E., HallettT.B., PowersK.A., KashubaA.D.Antiretroviral treatment of HIV-1 prevents transmission of HIV-1: where do we go from here?Lancet2013; 382: 1515–1524.
2.
MocroftA., VellaS., BenfieldT.L.Changing patterns of mortality across Europe in patients infected with HIV-1. EuroSIDA Study Group.Lancet1998; 352: 1725–1730.
3.
PalellaF.J.Jr., DelaneyK.M., MoormanA.C.Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators.N Engl J Med1998; 338: 853–860.
4.
d'Arminio MonforteA., SabinC.A., PhillipsA.The changing incidence of AIDS events in patients receiving highly active antiretroviral therapy.Arch Intern Med2005; 165: 416–423.
5.
MartinL.J., HoustonS., YasuiY., WildT.C., SaundersL.D.Rates of initial virological suppression and subsequent virological failure after initiating highly active antiretroviral therapy: the impact of aboriginal ethnicity and injection drug use.Curr HIV Res2010; 8: 649–658.
6.
CesconA.M., CooperC., ChanK.Factors associated with virological suppression among HIV-positive individuals on highly active antiretroviral therapy in a multi-site Canadian cohort.HIV Med2011; 12: 352–360.
7.
CesconA., KantersS., BrummeC.J.Trends in plasma HIV-RNA suppression and antiretroviral resistance in British Columbia, 1997-2010.J Acquir Immune Defic Syndr2014; 65: 107–114.
8.
RibaudoH.J., SmithK.Y., RobbinsG.K.Racial differences in response to antiretroviral therapy for HIV infection: an AIDS clinical trials group (ACTG) study analysis.Clin Infect Dis2013; 57: 1607–1617.
9.
AdelsonN.The embodiment of inequity: health disparities in aboriginal Canada.Can J Public Health2005; 96Suppl 2: S45–S61.
10.
Population-Specific HIV/AIDS Status Report - Aboriginal Peoples: Public Health Agency of Canada; 2010. (Accessed 21 February 2014.) Available from www.catie.ca/sites/default/files/26344.pdf.
11.
FrohlichK.L., RossN., RichmondC.Health disparities in Canada today: some evidence and a theoretical framework.Health Policy2006; 79: 132–143.
12.
TjepkemaM., WilkinsR., SenecalS., GuimondE., PenneyC.Mortality of urban Aboriginal adults in Canada, 1991-2001.Chronic Dis Can2010; 31: 4–21.
JaworskyD., MonetteL., RaboudJ.Comparison of late HIV diagnosis as a marker of care for Aboriginal versus non-Aboriginal people living with HIV in Ontario.Can J Infect Dis Med Microbiol2012; 23: e96–e102.
16.
LefebvreM.E., HughesC.A., YasuiY., SaundersL.D., HoustonS.Antiretroviral treatment outcomes among foreign-born and Aboriginal peoples living with HIV/ AIDS in northern Alberta.Can J Public Health2014; 105: e251–e257.
17.
MillerC.L., SpittalP.M., WoodE.Inadequacies in antiretroviral therapy use among Aboriginal and other Canadian populations.AIDS Care2006; 18: 968–976.
18.
LimaV.D., KretzP., PalepuA.Aboriginal status is a prognostic factor for mortality among antiretroviral naive HIV-positive individuals first initiating HAART.AIDS Res Ther2006; 3: 14.
19.
RaboudJ.M., RaeS., WoodsR.Consecutive rebounds in plasma viral load are associated with virological failure at 52 weeks among HIV-infected patients.AIDS2002; 16: 1627–1632.
20.
GreubG., Cozzi-LepriA., LedergerberB.Intermittent and sustained low-level HIV viral rebound in patients receiving potent antiretroviral therapy.AIDS2002; 16: 1967–1969.
21.
BenoitA.C., JaworskyD., BeaverK.Building Bridges: A model for community engagement in epidemiology research.24th Annual Canadian Conference on HIV/AIDS Research. 30 April – 3 May 2015, Toronto, ON, Canada. Abstract EPH53.
22.
NowgesicE.What does it mean to have an Aboriginal Health Epidemiology Model?Building Bridges Final Gathering. 30 March 2015, Toronto, Ontario, Canada.
23.
BenoitA.C., YoungerJ., BeaverK.Increased mortality among Aboriginal persons in a multisite cohort of people living with HIV in Canada.Can J Public Health2017; in press.
24.
PalmerA.K., KleinM.B., RaboudJ.Cohort profile: the Canadian Observational Cohort collaboration.Int J Epidemiol2011; 40: 25–32.
25.
FineJ.P., GrayR.J.A proportional hazards model for the subdistribution of a competing risk.J Am Stat Assoc1999; 94: 496–509.
26.
BartlettJ.W., TaylorJ.M.Missing covariates in competing risks analysis.Biostatistics2016; 17: 751–763.
27.
EricksonA., BeckerM., ShawS., KasperK., KeynanY.Substance use and its impact on care outcomes among HIV-infected individuals in Manitoba.AIDS Care2015; 27: 1168–1173.
28.
GerettiA.M., SmithC., HaberlA.Determinants of virological failure after successful viral load suppression in first-line highly active antiretroviral therapy.Antivir Ther2008; 13: 927–936.
29.
EyawoO., FernandesK.A., BrandsonE.K.Suboptimal use of HIV drug resistance testing in a universal health-care setting.AIDS Care2011; 23: 42–51.
30.
SmylieJ., FirestoneM.Back to the basics: identifying and addressing underlying challenges in achieving high quality and relevant health statistics for indigenous populations in Canada.Stat J IAOS2015; 31: 67–87.
31.
MaddenR., AxelssonP., KukutaiT.Statistics on indigenous peoples: international effort needed.Stat J IAOS2016; 32: 37–41.
32.
EliasB., BusbyK., MartensP.One little, too little: counting Canada's indigenous people for improved health reporting.Soc Sci Med2015; 138: 179–186.
RourkeS.B., GardnerS., BurchellA.N.Cohort profile: the Ontario HIV Treatment Network Cohort Study (OCS).Int J Epidemiol2013; 42: 402–411.
35.
ReadingC., BrennanR., MaschingR.Cultural concepts of care among Aboriginal people living with HIV and AIDS: A study by the Canadian Aboriginal AIDS Network.CJACBR2013; 5: 24–37.
36.
MarshT.N., CoholicD., Cote-MeekS., NajavitsL.M.Blending Aboriginal and Western healing methods to treat intergenerational trauma with substance use disorder in Aboriginal peoples who live in northeastern Ontario, Canada.Harm Reduct J2015; 12: 14.
37.
WilkP., CookeM.Collaborative public health system interventions for chronic disease prevention among urban Aboriginal people.International Indigenous Policy Journal2015; 6: 1–14.
